This review evaluates the expanding clinical use of JAK-STAT pathway inhibition across immune-mediated inflammatory diseases (IMIDs), covering approved agents, evolving selectivity, tissue-specific delivery, and new mechanisms of action since the first JAK inhibitor approval in 2011.
Over a dozen JAK inhibitors have received regulatory approval, with newer agents offering improved JAK selectivity and targeted tissue delivery aimed at enhancing efficacy and addressing safety concerns across a growing range of IMID indications.
As a narrative review, it does not provide pooled effect sizes or systematic evidence grading; conclusions on comparative efficacy and safety rely on the authors' synthesis rather than meta-analytic methods.
When selecting a JAK inhibitor for an IMID, consider newer agents with improved selectivity or tissue-specific delivery, which may offer a better efficacy-safety balance than first-generation pan-JAK inhibitors. Stay current with evolving indications, as the approved uses for this drug class continue to expand rapidly.
Explore related topics
